IL6 and Parkinson disease: This process involves the NF-κB signaling pathway in both in vivo and in vitro PD models, causing the inhibition of the production of pro-inflammatory enzymes (iNOS and COX-2) and pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) (Fu et al., 2015).